Chapel Hill-based Path BioAnalytics (PBA) has joined forces with Australian researchers to study a new drug to fight SARS-related Coronoavirus-2, the virus that causes COVID-19.
Read More
Path BioAnalytics (PBA) is teaming up with impact investors and a digital health company to find a cure for pancreatitis.
Read More
The firm received the license from Laurel Therapeutics, a global clinical-stage biopharmaceutical company in Hangzhou China. PBA will use its proprietary technology – an organoid platform using primary cells — to identify subpopulations of patients in which the drug candidate is effective.
Read More
